Results

Total Results: 2,080 records

Showing results for "drug".

121. Arthritis-Psoriatric Executive (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/arthritis-psoriatric_executive.pdf
     April 01, 2012 - 1 Comparative Effectiveness Review Number 54 Drug Therapy for Psoriatic Arthritis in Adults: Update … Food and Drug Administration (FDA) has approved adalimumab, etanercept, golimumab, and infliximab for … KQ 3: For patients with PsA, do drug therapies differ in harms, tolerability, patient adherence, or … KQ 4: What are the comparative benefits and harms of drug therapies for PsA in subgroups of patients … Drug Therapy for Psoriatic Arthritis in Adults: Update of a 2007 Report.

122. Topic Suggestion Description | Effective Health Care Program
     effectivehealthcare.ahrq.gov/get-involved/nominated-topics/1-which-patients-benefit-the-most-from-mtm-services-11-which-factors-or-combinations-of-factors-are-most-predictive-of-the-clinical-benefit-of-mtm-services-111-disease-factors-eg-diabetes-vs-copd-multi-morbidity-vs-single-dis
     July 28, 2010 - 2.2.What is the optimal timing of MTM services relative to events or diagnosis (e.g., initiation of drug … beneficiaries with 2 or more chronic conditions and high drug expenditures. … Appropriateness for EHC Program Does your question include a health care drug, intervention, device … therapy by including provisions for medication therapy management (MTM) within the Medicare Part D drug … current eligibility criteria limit the inclusion of patients to those with multi-morbidity and high drug

123. Infectious Disease Including HIV/AIDS #09 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/infectious-disease-horizon-scan-high-impact-1412.pdf
     December 22, 2014 - In October 2014, a new sofosbuvir drug combination drug was approved (Harvoni; Gilead Sciences) that … It has also been approved as part of a fixed-dose combination with the drug ledipasvir, a drug that … purportedly has a low drug-drug interaction profile, which could support its use in patients with … Gilead gets U.S. approval to sell new hepatitis C drug: drug is seen building on the highly successful … Food and Drug Administration (FDA).

124. Evidence-based Practice Center Systematic Review Protocol (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/migraine-prevention_research-protocol.pdf
     November 03, 2011 - Food and Drug Administration (FDA) for migraine prevention in adults come from different drug classes … surveillance, or interactive drug monitoring. … , patient education, drug surveillance, or interactive drug monitoring) influence results? … , patient education, drug surveillance, or interactive drug monitoring) influence results? … Regulating off-label drug use--rethinking the role of the FDA.

125. #14 SUBSTANCE ABUSE (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/substance-abuse-horizon-scan-high-impact-1406.pdf
     January 01, 2020 - Food and Drug Administration (FDA) bioequivalence study data were available for a drug or a pilot was … Narcan: FDA drug overview. [internet]. Silver Spring (MD): U.S. … Food and Drug Administration (FDA) [accessed 2014 May 05]. [2 p]. … Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER); 2014 Apr 3. … Holder urges use of drug to combat heroin overdoses.

126. Dia 1 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/ijzerman_ahrq-webinar-mcda.pdf
     January 01, 2011 - pressure high blood pressure No adverse events Out-of-Pocket Costs 5 US$ 3 US$ 5 US$ Drug … A Drug B Drug C All MCDA and CA methods decompose a decision problem into a set of criteria … pressure high blood pressure No adverse events Out-of-Pocket Costs 5 US$ 3 US$ 5 US$ Drug … A Drug B Drug C C1 = 0.5 C2 = 0.33 C3 = 0.17 L1.1 = 0.5 L1,2 = 0.25 L1,3 = 0.25 drug A

127. PULMONARY with "Discussions" in Exec Summary (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pulmonary_hi_impact.pdf
     April 01, 2012 - to determine whether they are potential candidates for the drug. … Food and Drug Administration (FDA); 2010 Apr 9. 39 p. … Food and Drug Administration (FDA); 2010 Apr 27. 35 p. … Available: http://www.vrtx.com/current-projects/drug- candidates/vx-770.html. 23. … /drug-candidates/vx-770.html http://investors.vrtx.com/releasedetail.cfm?

128. Communicating Harms and Benefits of Prescription Drugs to Healthcare Consumers (ppt file)
     effectivehealthcare.ahrq.gov/sites/default/files/communicating_risk_hickam.ppt
     December 01, 2006 - practice & research Morning Presentations Innovative Methods of Communicating Harms and Benefits of Drug

129. Survey of Medicare Part D Plans’ Medication Therapy Management Programs (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/medication-therapy-management-1_research-2007.pdf
     January 01, 2007 - Plans (PDP) and Medicare Advantage Drug Plans (MA-PD). … Role of the clinical pharmacist in improving drug therapy. … Fatal adverse drug events: the paradox of drug treatment. J Intern Med 2001;250(4):327-41. 19. … Adverse drug events in emergency department patients. … for and/or existence of drug-drug, drug- disease, or drug-food interactions or problems) 55.0 5.6

130. Comparative Effectiveness of Drug Therapy for Rheumatoid Arthritis in Adults – An Update to the 2007 Report | Effective Health Care (EHC) Program
     effectivehealthcare.ahrq.gov/products/rheumatoid-arthritis-medicine/research-protocol
     December 06, 2010 - Protocol Jun. 1, 2012 Systematic Review Jun. 7, 2013 Surveillance Report Comparative Effectiveness of Drug … Food and Drug Administration (FDA) for the treatment RA at the time of the first review. … The Key Questions (KQs) Question 1: For patients with RA, do drug therapies differ in their ability … Question 3: For patients with RA, do drug therapies differ in harms, tolerability, patient adherence … Food and Drug Administration (FDA).

131. Efficacy and Comparative Effectiveness of Off-Label Use of Atypical Antipsychotics – Update | Effective Health Care (EHC) Program
     effectivehealthcare.ahrq.gov/products/atypical-antipsychotics-off-label-update/research-protocol
     May 19, 2010 - Objectives for the Systematic Review Atypical antipsychotics are approved by the United States Food and Drug … To arrive at a quantitative measure, we will use the Jadad scale, which was developed for drug trials … The evidence of risks (adverse events) will be summarized within drug (each atypical antipsychotic separately … severely symptomatic persons have higher scores, a negative effect size indicates that the atypical drug

132. Migraine in Children: Preventive Pharmacologic Treatments | Effective Health Care (EHC) Program
     effectivehealthcare.ahrq.gov/products/migraine-prevention/research
     June 11, 2013 - Also eligible were studies that compared drugs with nonpharmacologic interventions or drug management … Multidisciplinary drug management was more effective than usual care in preventing migraine in children

133. Psoriatic Arthritis Surveillance Assesment_CER 54_Low (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/arthritis-psoriatric_surveillance.pdf
     March 01, 2013 - Psoriatic Arthritis Surveillance Assesment_CER 54_Low CER #54: Drug Therapy for Psoriatic Arthritis … Key Findings: - Key Question 1: Conclusion regarding biologic Disease- Modifying Antirheumatic Drug … This drug is not approved for PsA. … This drug is not approved for PsA. EPC Investigator felt the conclusions were up to date. … Drug Therapy for Psoriatic Arthritis in Adults: Update of a 2007 Report.

134. Disease-Modifying Antirheumatic Drugs (DMARDs) in Children With Juvenile Idiopathic Arthritis (JIA) | Effective Health Care (EHC) Program
     effectivehealthcare.ahrq.gov/products/juvenile-arthritis-dmards/research
     September 26, 2011 - There are few direct comparisons of DMARDs, and insufficient evidence to determine if any specific drug … or drug class has greater beneficial effects.

135. Comparative Effectiveness of Preventive Pharmacological Treatments for Migraine | Effective Health Care (EHC) Program
     effectivehealthcare.ahrq.gov/products/migraine-prevention/research-protocol
     November 03, 2011 - Food and Drug Administration (FDA) for migraine prevention in adults come from different drug classes … surveillance, or interactive drug monitoring. … , patient education, drug surveillance, or interactive drug monitoring) influence results? … , patient education, drug surveillance, or interactive drug monitoring) influence results? … Pharmacological classes for migraine prevention Drug, ATC Code* Class of Drug ANTIEPILEPTICS

136. Antipsychotics for the Prevention and Treatment of Delirium: A Systematic Review | Effective Health Care (EHC) Program
     effectivehealthcare.ahrq.gov/products/antipsychotics/research-protocol
     September 06, 2018 - Currently, there are no medications approved by the Food and Drug Administration for the prevention and … Comparators: KQ 1: Non-drug approaches to preventing delirium, placebo, active control, usual care … KQ 2: Non-drug approaches to treating delirium, placebo, active control, usual care Outcomes: … For KQ 2, we will include non-drug approaches to treating delirium, including placebo, active control … Does antipsychotic drug use increase the risk of long term mortality?

137. Medication-Therapy-Management Research-Protocol (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/medication-therapy-management_research-protocol.pdf
     January 01, 2014 - Background and Objectives for the Systematic Review The Medicare Prescription Drug, Improvement, … Public Law 108-173)1 established the requirements that Part D plan sponsors must meet with regard to drug … include providing education and counseling, improving medication adherence, and detecting adverse drug … substitution issue; complex regimen that can be simplified with same therapeutic benefit; and potential for drug-drug … : needed drug initiated; unnecessary drug discontinued; change in drug dose, form, or frequency; or

138. Topic Brief: Updating Treatments for Fecal Incontinence (pdf file)
     effectivehealthcare.ahrq.gov/system/files/docs/topic-brief-fecal-incontinence.pdf
     October 26, 2020 - 2020 1 ((anal or fecal or faecal) adj incontinen*).ti. (584) 2 (biofeedback or device* or diet* or drug … 2020 1 ((anal or fecal or faecal) adj incontinen*).ti. (15) 2 (biofeedback or device* or diet* or drug … incontinence OR fecal incontinence OR faecal incontinence ) AND ( biofeedback OR device OR diet OR drug … Does the nomination represent a health care drug, intervention, device, technology, or health care … Abbreviations: CCFIS = Cleveland clinical fecal incontinence score; FDA = food and drug administration

139. Topic Brief: Updating Treatments for Fecal Incontinence (pdf file)
     effectivehealthcare.ahrq.gov/system/files/docs/topic-brief-fecal-incontinence_2.pdf
     October 26, 2020 - 2020 1 ((anal or fecal or faecal) adj incontinen*).ti. (584) 2 (biofeedback or device* or diet* or drug … 2020 1 ((anal or fecal or faecal) adj incontinen*).ti. (15) 2 (biofeedback or device* or diet* or drug … incontinence OR fecal incontinence OR faecal incontinence ) AND ( biofeedback OR device OR diet OR drug … Does the nomination represent a health care drug, intervention, device, technology, or health care … Abbreviations: CCFIS = Cleveland clinical fecal incontinence score; FDA = food and drug administration

140. Topic Brief: Updating Treatments for Fecal Incontinence (pdf file)
     effectivehealthcare.ahrq.gov/system/files/docs/topic-brief-fecal-incontinence_1.pdf
     October 26, 2020 - 2020 1 ((anal or fecal or faecal) adj incontinen*).ti. (584) 2 (biofeedback or device* or diet* or drug … 2020 1 ((anal or fecal or faecal) adj incontinen*).ti. (15) 2 (biofeedback or device* or diet* or drug … incontinence OR fecal incontinence OR faecal incontinence ) AND ( biofeedback OR device OR diet OR drug … Does the nomination represent a health care drug, intervention, device, technology, or health care … Abbreviations: CCFIS = Cleveland clinical fecal incontinence score; FDA = food and drug administration